937630-96-1

Basic information

• Product Name: N-(3-Amino-phenyl)-3-morpholin-4-yl-propionamide
• Synonyms: N-(3-Amino-phenyl)-3-morpholin-4-yl-propionamide;N-(3-Aminophenyl)-3-morpholino-propanamide
• CAS NO: 937630-96-1
• Molecular Formula: C₁₃H₁₉N₃O₂
• Molecular Weight: 249.31
• Mol File: 937630-96-1.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(3-Amino-phenyl)-3-morpholin-4-yl-propionamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-Amino-phenyl)-3-morpholin-4-yl-propionamide(937630-96-1)
• EPA Substance Registry System: N-(3-Amino-phenyl)-3-morpholin-4-yl-propionamide(937630-96-1)

Safety Data

• Hazardous Substances Data: 937630-96-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C13H19N3O2.2ClH/c14-11-2-1-3-12(10-11)15-13(17)4-5-16-6-8-18-9-7-16;;/h1-3,10H,4-9,14H2,(H,15,17);2*1H

Upstream product

• 60284-53-9 3-chloro-N-(3-nitrophenyl)propanamide 
• 99-09-2 3-nitro-aniline 
• 1586764-64-8 3-morpholino-N-(3-nitrophenyl)propanamide 

Downstream Products

• 1446421-11-9 N-(3-(3-(4-(bis(2-chloroethyl)amino)phenyl)ureido)phenyl)-3-morpholinopropanamide 

Relevant articles and documents

Design and synthesis of potent antitumor water-soluble phenyl N-mustard-benzenealkylamide conjugates via a bioisostere approach

A series of new, water-soluble phenyl N-mustard-benzenealkylamide conjugates containing hydrophilic ω-dialkylaminoalkylamide or ω-cyclic aminoalkylamide moieties were synthesized via a bioisostere approach. These compounds have a broad spectrum of antitumor activity against a panel of human tumor cell lines. Of these derivatives, compound 18b effectively suppressed the growth of colon cancer (HCT-116), prostate cancer (PC3), and lung cancer (H460) xenografts. The growth of HCT-116 xenografts was almost completely suppressed when co-treated with compound 18b and 5-fluorouracil. Furthermore, compound 18b can induce DNA cross-linking and cell-cycle arrest at the G2/M phase. Early preclinical studies, including pharmacokinetics in rats, inhibition of the hERG, and 14 days of acute intravenous injection toxicity, suggest that compound 18b is a promising candidate for further preclinical studies.